# Ventyx Biosciences Inc. (VTYX)

Source: https://www.quantisnow.com/company/VTYX
Generated: 2026-11-09T21:17:05.632Z

- Ticker: VTYX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2021
- Website: ventyxbio.com

## About

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that has completed phase I clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases. In addition, the company develops CNS-penetrant NLRP3 inhibitors. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.

## Latest VTYX news and filings

- 2026-03-16 16:48 UTC [SEC Form 15-12G filed by Ventyx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-ventyx-biosciences-inc-6448899)
- 2026-03-09 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Ventyx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-ventyx-biosciences-inc-6436052)
- 2026-03-09 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Ventyx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-ventyx-biosciences-inc-6436051)
- 2026-03-05 14:00 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Ventyx Biosciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-ventyx-biosciences-inc-6431812)
- 2026-03-04 21:38 UTC [SEC Form 4] [Senior VP, Finance Gonzales Roy returned 5,313 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/senior-vp-finance-gonzales-roy-returned-5313-shares-to-the-6429916)
- 2026-03-04 21:35 UTC [SEC Form 4] [Director Subramaniam Somu returned 3,337,495 shares to the company (SEC Form 4)](https://www.quantisnow.com/insight/director-subramaniam-somu-returned-3337495-shares-to-the-company-sec-6429881)
- 2026-03-04 21:33 UTC [SEC Form 4] [SEC Form 4 filed by Director White William Richard](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-white-william-richard-6429858)
- 2026-03-04 21:30 UTC [SEC Form 4] [SEC Form 4 filed by Chief Operating Officer Moore Matthew Richard](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-operating-officer-moore-matthew-6429808)
- 2026-03-04 21:28 UTC [SEC Form 4] [SEC Form 4 filed by Director Cadoret-Manier Onaiza](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-cadoret-manier-onaiza-6429726)
- 2026-03-04 21:26 UTC [SEC Form 4] [SEC Form 4 filed by Director Hulme Allison](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-hulme-allison-6429698)
- 2026-03-04 21:23 UTC [SEC Form 4] [Director Gujrathi Sheila returned 130,000 shares to the company (SEC Form 4)](https://www.quantisnow.com/insight/director-gujrathi-sheila-returned-130000-shares-to-the-company-sec-6429659)
- 2026-03-04 21:20 UTC [SEC Form 4] [CHIEF SCIENTIFIC OFFICER Nuss John returned 489,481 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-nuss-john-returned-489481-shares-to-the-6429602)
- 2026-03-04 21:17 UTC [SEC Form 4] [CEO AND PRESIDENT Mohan Raju returned 2,372,863 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/ceo-and-president-mohan-raju-returned-2372863-shares-to-the-6429561)
- 2026-03-04 21:15 UTC [SEC Form 4] [Chief Medical Officer Forman Mark S returned 6,000 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-forman-mark-s-returned-6000-shares-to-6429506)
- 2026-03-04 17:06 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Ventyx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-ventyx-biosciences-inc-6428862)
- 2026-03-04 17:05 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Ventyx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-ventyx-biosciences-inc-6428859)
- 2026-03-04 17:01 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Ventyx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-ventyx-biosciences-inc-6428857)
- 2026-03-04 16:59 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Ventyx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-ventyx-biosciences-inc-6428851)
- 2026-03-04 16:57 UTC [SEC Form POS AM filed by Ventyx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-ventyx-biosciences-inc-6428850)
- 2026-03-04 16:55 UTC [SEC Form POS AM filed by Ventyx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-ventyx-biosciences-inc-6428849)
- 2026-03-04 14:37 UTC [SEC Form 25-NSE filed by Ventyx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-ventyx-biosciences-inc-6428721)
- 2026-03-04 14:22 UTC [SEC Form 8-K] [Ventyx Biosciences Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year](https://www.quantisnow.com/insight/ventyx-biosciences-inc-filed-sec-form-8-k-completion-of-acquisition-6428692)
- 2026-03-03 22:02 UTC [SEC Form 8-K] [SEC Form 8-K filed by Ventyx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-ventyx-biosciences-inc-6426287)
- 2026-03-03 21:49 UTC [SEC Form 4] [Director Subramaniam Somu disposed of 694,718 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-subramaniam-somu-disposed-of-694718-shares-sec-form-4-6426072)
- 2026-02-23 21:29 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Ventyx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-ventyx-biosciences-inc-6407511)
- 2026-02-23 21:26 UTC [SEC Form 8-K] [SEC Form 8-K filed by Ventyx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-ventyx-biosciences-inc-6407487)
- 2026-02-19 21:06 UTC [SEC Form SCHEDULE 13G filed by Ventyx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-ventyx-biosciences-inc-6402341)
- 2026-02-06 21:13 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Ventyx Biosciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-ventyx-biosciences-inc-6379798)
- 2026-02-05 21:53 UTC [SEC Form SCHEDULE 13G filed by Ventyx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-ventyx-biosciences-inc-6378333)
- 2026-02-02 21:05 UTC [SEC Form DEFM14A] [SEC Form DEFM14A filed by Ventyx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-defm14a-filed-by-ventyx-biosciences-inc-6369896)
- 2026-01-30 00:59 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Ventyx Biosciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-ventyx-biosciences-inc-6366663)
- 2026-01-22 22:29 UTC [SEC Form PREM14A filed by Ventyx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-prem14a-filed-by-ventyx-biosciences-inc-6358176)
- 2026-01-22 21:18 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Ventyx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-ventyx-biosciences-inc-6357865)
- 2026-01-22 21:16 UTC [SEC Form 8-K] [SEC Form 8-K filed by Ventyx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-ventyx-biosciences-inc-6357853)
- 2026-01-10 02:48 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Ventyx Biosciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-ventyx-biosciences-inc-6345036)
- 2026-01-08 02:24 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Ventyx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-ventyx-biosciences-inc-6341978)
- 2026-01-08 02:22 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Ventyx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-ventyx-biosciences-inc-6341977)
- 2026-01-08 02:28 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Ventyx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-ventyx-biosciences-inc-6341976)
- 2026-01-08 02:29 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Ventyx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-ventyx-biosciences-inc-6341975)
- 2026-01-08 02:26 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Ventyx Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-ventyx-biosciences-inc-6341971)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/VTYX
- Earnings history: https://www.quantisnow.com/earnings/VTYX
- Dividend history: https://www.quantisnow.com/dividends/VTYX
- Insider transactions: https://www.quantisnow.com/insiders/VTYX
- Options chain: https://www.quantisnow.com/options/VTYX
- SEC 8-K filings only: https://www.quantisnow.com/company/VTYX/8-k
- RSS and alerts for VTYX: https://www.quantisnow.com/docs/rss-feeds.md